Navigation Links
Latest advances in gene therapy for ocular disease are highlighted in Human Gene Therapy
Date:5/9/2011

New Rochelle, NY, May 9, 2011Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body. A series of articles available online ahead of print in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com), highlight several exciting developments in ocular gene therapy. The articles are available free online at www.liebertpub.com/hum

Two review articles describe the unique opportunities for ocular gene therapy. "Gene Transfer for Neovascular Age-Related Macular Degeneration" by Peter Campochiaro shows the potential for long-term delivery of proteins to control abnormal growth of blood vessels. In "Surgical Approaches to Gene and Stem Cell Therapy for Retinal Disease," Stout and Francis outline the many factors that contribute to the successful application of gene therapy to treat ocular disease.

Several research articles illustrate the broad scope of uses and delivery methods for ocular gene therapy. Miyazaki et al. show that neuroprotective gene therapy could reduce cell death in the retinas of rats exposed to damaging hypertension and infections in "Pigment Epithelium-Derived Factor Gene Therapy Targeting Retinal Ganglion Cell Injuries: Neuroprotection against Loss of Function in Two Animal Models." Goldmann et al. report on the therapeutic potential of a gene therapy drug to treat retinal disease caused by a genetic mutation in "PTC124-Mediated Translational Readthrough of a Nonsense Mutation Causing Usher Syndrome Type 1C."

Fuchsluger et al. describe gene therapy to prevent cell death in the cornea, in "Corneal Endothelial Cells are Protected from Apoptosis by Gene Therapy." Mao et al. describe the delivery of a normal copy of the rhodopsin gene to mice with ocular disease caused by a mutated RHO gene and its ability to slow the rate of retinal degeneration in "AAV Delivery of Wild-Type Rhodopsin Preserves Retinal Function in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa."

In the Brief Report "Gene Therapy in Ophthalmology: Validation on Cultured Retinal Cells and Explants from Postmortem Human Eyes," Fradot and colleagues show how gene therapy strategies can be developed and refined using cultured cells and explants from human eyes harvested after death to limit research studies done in primates.

"The most dramatic clinical success of in vivo gene therapy has been realized using AAV vectors in the treatment of a rare inherited form of congenital blindness; some level of functional improvement was realized in three independent trials. A number of scientists from around the world are progressing in vivo gene therapy into a number of other ocular disorders. This issue of the Journal captures some of these exiting new directions," says James M. Wilson, M.D., Ph.D., Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Humpback whale songs spread eastward like the latest pop tune
2. Latest report on North American industrial pollution reveals impacts on our shared water environment
3. Latest hands-free electronic water faucets found to be hindrance, not help, in infection control
4. New Brain Connectivity journal captures latest advances in neuroscience research
5. 1,500 worldwide experts debate the latest advances in breast pathologies treatments in Valencia
6. Stanford pollster to discuss latest survey on global warming
7. Survey reports latest honey bee losses
8. Latest research on GI health presented at DDW 2010
9. Database gives access to the latest findings about the tree of life
10. New edition of popular lab manual presents latest techniques for probing cellular dynamics
11. Latest analysis confirms suboptimal vitamin D levels in millions of US children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Latest advances in gene therapy for ocular disease are highlighted in Human Gene Therapy
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific ... LC-MS, host live demos and poster sessions, and present on the analysis of ... takes place March 6 to 10 at the Georgia World Congress Center in ...
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
Breaking Biology Technology: